A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
Terminated · Phase 2 · NCT05061420
Conditions: Squamous Cell Carcinoma of Head and Neck
At a glance
- Research payments reported, 2025
- $7,228
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 59
About the trial
- Sponsor
- Sanofi (with Merck Sharp & Dohme LLC)
- Tested
- Pembrolizumab (drug), SAR444245 (Thor-707) (drug), Cetuximab (drug)
- Dates
- Started 2021-10-08; completion 2024-11-26
- Results posted
- Yes
The study was a phase 2 multi-cohort, non-randomized, open-label, multi-center study assessing the clinical benefit of SAR444245 combined with other anticancer therapies for the treatment of participants aged 18 years and older with HNSCC. This study was structured as a master protocol for the investigation of SAR444245 with other anticancer therapies. Substudy 1-Cohort A1 aimed to establish proof-of-concept that SAR444245 combined with the anti-PD1 antibody pembrolizumab, will result in a significant increase in the observed number of objective responses in trial participants with HNSCC who were treatment-naïve for recurrent and/or metastatic (R/M) disease. Substudy 4-Cohort B1 aimed to …
From ClinicalTrials.gov, last updated 2025-09-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $7,228 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Jefferson Health Nephrology $7,228
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.